Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Cymbalta for maintenance of major depression

The FDA approves US-based Eli Lilly's Cymbalta for the maintenance treatment of major depressive disorder in adults

The FDA has approved US-based Eli Lilly's Cymbalta (duloxetine) for the maintenance treatment of major depressive disorder (MDD) in adults.

The efficacy and safety of Cymbalta for maintenance treatment of major depression was established in a double-blind, placebo-controlled clinical trial. 

The trial assessed 533 patients with major depression, who received 60 mg of Cymbalta once daily. After 12 weeks, 278 patients met the criteria for entering the continuation phase and were randomly assigned to either Cymbalta at the same dose or to a sugar pill for six months.

Patients on the Cymbalta arm experienced a statistically longer time to relapse of depression than those receiving a placebo. Relapse was defined as an increase of two or more points on the Clinical Global Impression Severity scale (CGI-S), compared with that obtained at week 12, and also meeting the criteria for major depressive disorder for two consecutive visits.

Cymbalta is already approved for the acute treatment of major depressive disorder, the management of diabetic peripheral neuropathic pain, and for the treatment of generalised anxiety disorder in adults. More than nine million adults in the US have been prescribed the drug since approval.

Dr Doug Williamson, Cymbalta associate medical director for Lilly, said: "Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern. This approval from the FDA is important because data from our Cymbalta clinical trial demonstrate that continuing to treat the patient delays the time to possible relapse."

In Q3 FY07, sales of Cymbalta rose 47 per cent to reach USD 513.2m.

30th November 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics